Resveratrol: Sirtuins, Cardiovascular, And The Bioavailability Problem

Resveratrol became famous as the red wine molecule, but the research is messier and more controversial than the marketing suggests.

In this post, we will discuss what resveratrol actually does, why bioavailability is the central problem, and how to interpret the cardiovascular and longevity evidence.

---

What Is Resveratrol

Resveratrol is a polyphenol found in grapes, red wine, peanuts, and Japanese knotweed (Polygonum cuspidatum). R

It gained attention after studies suggested it extended lifespan in yeast and other organisms. R

Much of the early hype was driven by research on sirtuin activation. R

Sirtuin Activation Controversy

Resveratrol was initially reported to directly activate SIRT1, a NAD+-dependent deacetylase linked to longevity. R

Later studies showed that early results were partly artifacts caused by fluorescent synthetic substrates that resveratrol bound to directly. R

The current consensus is that resveratrol likely works through indirect mechanisms, including AMPK activation and phosphodiesterase inhibition, rather than direct SIRT1 activation. R

This controversy is central to understanding why resveratrol has not lived up to all of its early promises. R

The NAD+ Connection

Sirtuins require NAD+ as a cofactor. R

Resveratrol may indirectly influence NAD+ levels by stimulating NADH oxidation and activating AMPK, which in turn influences NAD+ salvage enzymes. R

This has led to the idea that combining resveratrol with NAD+ precursors like NMN or NR could be synergistic. R

However, direct clinical evidence for this combination is limited. R

Cardiovascular Effects

Resveratrol has shown potential for improving cardiovascular health by targeting the endothelium. R

It promotes nitric oxide bioavailability by upregulating endothelial nitric oxide synthase (eNOS) and inhibiting oxidative stress. R

Systematic reviews indicate that resveratrol may improve blood pressure and endothelial function in people with type 2 diabetes or high cardiovascular risk. R

However, clinical results remain inconsistent due to variability in dosing, study design, and bioavailability. R

The Bioavailability Problem

The most significant hurdle for resveratrol is poor oral bioavailability. R

When ingested, resveratrol is rapidly metabolized in the intestines and liver via glucuronidation and sulfation. R

Plasma concentrations of free, unmetabolized resveratrol are often well below the levels used in cell studies. R

Solutions

Micronized resveratrol. Reduces particle size to improve absorption. R Piperine. Inhibits glucuronidation, similar to its effect on curcumin. R Liposomal formulations. Protect resveratrol from digestion. R

Forms And Dosing

Most clinical trials use trans-resveratrol, the active isomer. R

Polygonum cuspidatum extract is a natural source of trans-resveratrol, but standardization varies. R

Doses in clinical trials range from 20 mg to 5 g per day. R

Resveratrol is generally well tolerated at doses up to 1-2 g per day. R

High doses may interact with cytochrome P450 enzymes and affect drug metabolism. R

Mechanisms Of Action

Simple:

Resveratrol may activate AMPK and other metabolic pathways. It supports endothelial nitric oxide production. It has antioxidant effects through direct free radical scavenging and Nrf2 activation.

Advanced:

AMPK activation. Resveratrol activates AMPK, which regulates energy metabolism, mitochondrial biogenesis, and insulin sensitivity. R eNOS upregulation. Resveratrol increases endothelial nitric oxide synthase expression and activity, improving vascular function. R Nrf2 signaling. Resveratrol activates Nrf2, increasing expression of antioxidant response genes. R SIRT1 indirect effects. While direct activation is disputed, resveratrol may support sirtuin activity indirectly through NAD+ metabolism and AMPK. R

Genetics

SIRT1

SIRT1 is the most studied sirtuin in the context of resveratrol. R

Genetic variation in SIRT1 may influence response to resveratrol and related compounds. R

AMPK

AMPK is a cellular energy sensor that resveratrol activates. R

AMPK genetic variants may affect metabolic response. R

CYP1A2 / CYP3A4

Resveratrol is metabolized partly by cytochrome P450 enzymes. R

Genetic variation may alter metabolism and drug interactions. R

More Research

Cancer. Preclinical studies show anti-proliferative and pro-apoptotic effects, but human clinical translation has been limited by bioavailability. R Neuroprotection. Resveratrol has been studied for Alzheimer's and Parkinson's disease, with preliminary but inconsistent results. R Conflicts of interest. Dr. David Sinclair's early work launched the field, but his financial ties to longevity supplement companies have generated criticism and skepticism. R Testing. For biomarker testing I use the Inflammation Panel and Cardiovascular Panel to assess endothelial and inflammatory status.